Publications by authors named "Arne Vandevelde"
Article Synopsis
- The study aims to enhance the consistency of interpreting anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibody tests for diagnosing antiphospholipid syndrome (APS) by establishing moderate and high thresholds using various testing methods.
- Research involved analyzing samples from 381 APS patients and 727 controls across four different immunoassay systems to calculate likelihood ratios (LRs) that could distinguish between disease states.
- The findings show that the defined thresholds lead to better harmonization in interpreting antibody levels, particularly for IgG aCL and aβ2GPI, suggesting a more reliable method for diagnosing APS that requires further validation.
Background: The added value of antiphosphatidylserine/prothrombin antibodies (aPS/PT) in the diagnostic workup of antiphospholipid syndrome (APS) is unclear. Currently, diagnosis of thrombotic APS (TAPS) and obstetric APS (OAPS) requires persistent presence of lupus anticoagulant (LAC), anticardiolipin (aCL) immunoglobulin (Ig) G/IgM, or anti-β2-glycoprotein I (aβ2GPI) IgG/IgM antibodies.
Objectives: To evaluate the role of aPS/PT IgG and IgM in OAPS.
Background: The antiphospholipid syndrome (APS) is classified by the presence of antiphospholipid antibodies (aPL) and thrombotic and/or adverse obstetric outcomes. The diagnosis and risk assessment of APS is challenging. This systematic review investigated if the thrombin generation (TG) assay could be helpful for APS diagnosis and risk assessment.
View Article and Find Full Text PDFBackground: Diagnosis of antiphospholipid syndrome (APS) requires persistent presence of lupus anticoagulant (LAC), anticardiolipin (aCL) IgG/IgM, or anti-β2 glycoprotein I (aβ2GPI) IgG/IgM antibodies. Other antiphospholipid antibodies (aPL) such as antiphosphatidylserine/prothrombin antibodies (aPS/PT) are promising in assessment of thrombotic APS (TAPS).
Aim: To evaluate the added value of aPS/PT IgG and IgM in TAPS.
Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion (thrombosis and/or pregnancy morbidity), combined with persistently circulating antiphospholipid antibodies (aPL). Currently, laboratory criteria aPL consist of lupus anticoagulant (LAC), anticardiolipin antibodies (aCL) IgG/IgM, and anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM. Diagnosis and risk stratification of APS are complex and efforts to standardize and optimize laboratory tests have been ongoing since the initial description of the syndrome.
View Article and Find Full Text PDFIntroduction: Global coagulation assays may be of added value to the anti-Xa assay for monitoring heparin therapy. Unlike most testing methods, the thrombin generation assay (TGA) has the ability to assess the overall function of the hemostatic system, which provides information on the anticoagulation status of patients. We compared the TGA, measured with ST Genesia STG-DrugScreen reagent, with the anti-Xa assay for monitoring heparin therapy in inflammatory and non-inflammatory patients.
View Article and Find Full Text PDFBackground: Antiβ2glycoprotein I (aβ2GPI) and anticardiolipin (aCL) IgG/IgM show differences in positive/negative agreement and titers between solid phase platforms. Method-specific semiquantitative categorization of titers could improve and harmonize the interpretation across platforms.
Aim: To evaluate the traditional 40/80-unit thresholds used for aCL and aβ2GPI for categorization into moderate/high positivity with different analytical systems, and to compare with alternative thresholds.